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Abstract
Background: It is unclear why the severity of influenza varies in healthy adults or why the burden of severe influenza shifts
to young adults when pandemic strains emerge. One possibility is that cross-protective T cell responses wane in this age
group in the absence of recent infection. We therefore compared the acute cellular immune response in previously healthy
adults with severe versus mild pandemic H1N1 infection.
Methods and Principal Findings: 49 previously healthy adults admitted to the National Hospital of Tropical Diseases, Viet
Nam with RT-PCR-confirmed 2009 H1N1 infection were prospectively enrolled. 39 recovered quickly whereas 10 developed
severe symptoms requiring supplemental oxygen and prolonged hospitalization. Peripheral blood lymphocyte subset
counts and activation (HLADR, CD38) and differentiation (CD27, CD28) marker expression were determined on days 0, 2, 5,
10, 14 and 28 by flow cytometry. NK, CD4 and CD8 lymphopenia developed in 100%, 90% and 60% of severe cases versus
13% (p,0.001), 28%, (p=0.001) and 18% (p=0.014) of mild cases. CD4 and NK counts normalized following recovery. B cell
counts were not significantly associated with severity. CD8 activation peaked 6–8 days after mild influenza onset, when 13%
(6–22%) were HLADR+CD38+, and was accompanied by a significant loss of resting/CD27+CD28+ cells without
accumulation of CD27+CD282 or CD272CD282 cells. In severe influenza CD8 activation peaked more than 9 days
post-onset, and/or was excessive (30–90% HLADR+CD38+) in association with accumulation of CD27+CD282 cells and
maintenance of CD8 counts.
Conclusion: Severe influenza is associated with transient T and NK cell deficiency. CD8 phenotype changes during mild
influenza are consistent with a rapidly resolving memory response whereas in severe influenza activation is either delayed or
excessive, and partially differentiated cells accumulate within blood indicating that recruitment of effector cells to the lung
could be impaired.
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Introduction
In March 2009 a novel influenza A virus (A/California/04/
2009(H1N1): 2009 H1N1) was introduced into the human
population and then spread globally. It was first detected in Viet
Nam in Ho Chi Minh City in May 2009 and in Ha Noi in June
[1]. This 2009 H1N1 virus contained a unique combination of
gene segments from North American classical swine H1N1,
Eurasian swine H1N1 and triple-reassortant swine H1N2 lineages
[2] including antigenically novel haemagglutinin (HA) [2] and
neuraminidase (NA) proteins [3]. Accordingly, the very small
proportion of people that had detectable neutralizing or NA-
inhibiting antibodies prior to the pandemic were elderly and likely
to have been infected with H1N1 viruses closely related to those
circulating between 1918 and 1957 [3–6].
The medically attended case fatality rate was less than 0.05%
during the first wave of the pandemic, which is low compared to
previous pandemics [7–9]. However, up to a third of severe and
fatal cases were previously healthy young to middle-aged persons,
a group that is generally spared during seasonal epidemics, which
predominantly affect the very young because they are immuno-
logically naı ¨ve and the elderly because of immune-senescence
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31535[7,10–11]. A similar but stronger trend was seen during the 1918
pandemic when mortality was high in the very young, adults aged
20–40 years and the elderly with relative sparing of children and
older adults, resulting in a W-shaped mortality curve [12]. It’s
unclear why outcomes vary in healthy adults or why the burden of
severe influenza sometimes shifts to young adults when pandemic
strains emerge. A number of potential and possibly interacting
explanations have been proposed. These include: exposure of
older adults to similar stains in past decades, i.e. influenza
recycling [13]; age-related differences in bacterial carriage and
superinfection [13]; putative age-related differences in immune
regulation that render children less susceptible to immune
pathology [14], and protection by cross-reactive immune respons-
es induced by prior seasonal influenza exposure [15]. Given that
most people have had influenza by the age of 6 [16], an extension
of the latter theory must be that cross-reactive immune responses
wane.
CD8 T cells are important mediators of cross-reactive clinical
influenza immunity in animal models whereby memory T cells
recognize conserved viral proteins and limit virus growth such that
viral loads decline more rapidly and clinical symptoms are reduced
[17–21]. Human CD8 T cells kill influenza A virus infected cells in
vitro and are associated with faster clearance of an antigenically
distinct attenuated virus strain in vivo [22] but their contribution to
clinical protection is debated. It has been suggested that cross-
reactive T cells contribute little to clinical protection against
pandemic viruses since morbidity and mortality were high in 1918,
1957, and 1968 when H1N1, H2N2 and H3N2 emerged [23].
However, adults with recent seasonal influenza were less likely to
develop influenza during the 1957 [24] and 1968 pandemics [25]
suggesting that cross-protection exists, although immune responses
were not compared to verify this. Limited data also indicate that
influenza-specific CD8 cytotoxic T cell activity declines sharply
after infection [26] such that age groups with low seasonal
influenza infection rates may be more susceptible to clinical illness
during pandemics. The few studies that have used serology to
identify asymptomatic as well as symptomatic seasonal influenza
infections in the community find that infection rates decline with
age or show a wave like pattern, with rates being lowest in young
adults [27–28]. We have also observed this wave-like pattern in a
Vietnamese community followed since 2007 (Horby et al in
preparation).
To investigate whether the occurrence of severe 2009 H1N1
pandemic influenza infection in previously healthy adults is
associated with cellular immune responses we examined the
absolute number, and activation and differentiation status of
peripheral blood lymphocyte subsets over the course of severe
versus mild illness. We focus on CD8 T cells because they can
recognize the highly conserved internal influenza proteins and
thereby have greater potential to recognize pandemic 2009 H1N1.
HLA-DR and CD38 co-staining was used to estimate the
percentage responding to influenza since the vast majority of CD8
T cells co-expressing these markers are specific for the infecting
agent [29]. CD28 and CD27 co-staining was used to assess CD8 T
cell differentiation as the successive loss of these co-stimulatory
molecules following activation marks the acquisition of proliferative
capacity followed by cytotoxic/antiviral function [30–31].
Results
Clinical characteristics of patients classified as severe
versus mild influenza
Between 28 September 2009 and 23 January 2010 231 pa-
tients with suspected influenza were screened, 114 (49%) had
virologically confirmed 2009 H1N1 infection, and 62 (54%) were
enrolled. Thirteen patients were excluded from analysis in this
study, 12 because they had pre-existing systemic or respiratory
conditions and one because they were aged ,15 years (Figure S1).
The pre-existing conditions were pregnancy (2), leukemia (3),
laryngopharynx cancer (1), hypertension (1), congenital heart
disease (1), chronic sinusitis (3), and asthma (1). None of the
patients were obese, defined as body mass index (BMI) $30
according to BMI classification of the WHO Global Database on
BMI. Forty nine (79%) of the enrolled patients were previously
healthy adults of which 10 had severe illness and 39 mild illness.
Two of the patients with severe illness died, both were females, one
aged 23 and the other 42 years. Severe and mild patients were not
significantly different in terms of age or sex (Table 1). The number
of days from onset to admission and spent in hospital were both
significantly greater for severely ill patients (Table 1). All patients
with mild illness had recovered and were discharged within 2
weeks of onset whereas 5 of the 8 surviving severe patients were
still admitted at this time. Tachypnea, tachycardia and hypoxemia
were significantly more common in patients with severe illness,
both at enrolment and during admission, consistent with the
inclusion criteria (Table 1). Patients with severe illness received
oxygen for a median of 4 days (1–11 days) and 3 were
mechanically ventilated. The adapted PMEWS, a clinical severity
score, was higher for severely ill patients (Table 1).
The median day of illness when viral RNA was last detected in
nose and/or throat swabs was 5 (3–9) with no significant difference
between severe and mild cases (Figure 1, p=0.102). There were
insufficient samples with detectable viral loads to investigate the
relationship with severity; however we could not detect any
significant difference in Ct values for CDC influenza A realtime
RT-PCR with respiratory samples from severe versus mild patients
(data not shown). Only one patient had influenza virus RNA
Table 1. Patient characteristics.
Mild Severe p
Median (10–90% range)
Age 27.4 (19.2–37.1) 36.5 (20.2–56.3) 0.142
BMI 20.1 (16.8–25.3) 19.1 (18.0–20.4) 0.608
Days Ill at Admission 2 (1–4) 3(2–6) 0.003
Days Ill at Enrollment 3 (2–4) 5.5 (3.1–9) ,0.001
Days hospitalized 7 (5–12) 14 (8–17) 0.001
adapted PMEWS* 3 (2–6) 9 (6–18) ,0.001
n/N (%)
Male 15/39 (38.5) 5/10 (50.0) 0.720
Status at enrolment
Temperature $38uC 12/39 (30.8) 6/10 (60.0) 0.141
Tachypnea (rpm.30) 0/39 (0.0) 5/10 (50.0) ,0.001
Hypoxemia (SpO2 ,=92) 0/39 (0.0) 3/10 (30.0) 0.007
Tachycardia (bpm.100) 1/38 (2.6) 5/10 (50.0) 0.001
Status during admission
Tachypnea 0/39 (0.0) 6/10 (60.0) ,0.001
Hypoxemia 1/39 (2.6) 6/10 (60.0) ,0.001
Tachycardia 3/39 (7.7) 8/10 (80.0) ,0.001
*adapted PMEWS=adapted pandemic medical early warning score as defined
in the methods.
doi:10.1371/journal.pone.0031535.t001
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shown).
Absolute lymphocyte subset counts in severe versus mild
influenza
Lymphopenia was significantly more common in patients with
severe illness at enrolment and during admission, but not at follow-
up (Table 2). Lymphopenia was mainly due to low CD4 and NK
cell counts, which fell below the normal range in 90% and 100%
of severe patients, respectively, reflecting significantly lower nadir
levels than in mild patients (Table 2, Figure 2 a&b). CD4 and NK
counts were also significantly associated with the adapted PMEWS
(Figure 2d&e). CD4 (Figure S2) but not NK counts (data not
shown) were associated with the cycle threshold (Ct) value in the
CDC influenza A RT-PCR, a semi-quantitative indicator of the
amount of viral RNA in swabs. CD8 lymphopenia was detected in
6 (60%) of the severe patients compared to 7 (18%) of the mild
patients (Table 2) but CD8 counts were normal or high over the
course of acute illness in the remaining 4 severe patients (Figure 1c)
such that median counts did not differ significantly between severe
and mild patients (Table 2). CD4:CD8 ratios were significantly
lower in severely ill patients at enrolment (p=0.016, data not
shown) and during admission (Table 2), when 70% of severe versus
16% of mild patients had ratios less than 1 (p=0.002). B cell
lymphopenia was detected in only 2 severe patients, of which 1
had B cell lymphopenia following recovery, and B cell counts did
not differ significantly between severe and mild patients (Table 2).
Since severely ill patients presented later, lymphocyte counts
were compared for severe versus mild patients tested on equivalent
days since fever onset (Figure 2 a&b). CD4 counts were
significantly lower in severe compared to mild patients on days
4–5 (p=0.014); 6–8 (p=0.032) and days 9–11 post-onset
(p=0.027) but not on days 30–50 (p=0.775). NK cell counts
were also significantly lower in severe patients on days 4–5
(p,0.001), 6–8 (p=0.018) and 9–11 (p=0.036) but not on days
30–50 post onset (p=0.775). In patients with mild illness CD4
counts were lower 1–3 days compared to 6–8 days post-onset
(p=0.009), when levels were similar to those following recovery
(p=0.780 )(Figure 2a). Although CD4 counts also increased with
time since onset in severe patients, half were still CD4 lymp-
hopenic 9–11 days post-onset.
CD8 T cell activation and differentiation during mild
influenza
In patients with mild illness the percentage and absolute count
of CD8 T cells expressing activation markers CD38 and HLADR
was significantly higher 1–3 days post onset than 30–50 days post-
onset, i.e. following recovery (Figure 3, Figure S3). CD38+HLA-
DR+ CD8 frequencies peaked 6–8 days post-onset when the mean
was 13% (95%CI 6–22%) of CD8 T cells or 70 cells/ml (95%CI
21–127cells/ml) were positive (Figure 3). At the earliest times post-
onset a higher percentage of cells expressed CD38 alone than
expressed CD38 and HLADR, consistent with this being a marker
expressed earlier after activation (Figure 3a). The percentage of
CD8 T cells with a resting CD27+CD28+ phenotype was
significantly lower at 1–3 days post-onset than at later times and
returned to post-recovery levels by 6–8 days post-onset (Figure 3a,
Figure S3). In accompaniment the percentages with CD27+
CD282 (intermediate differentiation) and CD272CD282 (late
differentiation) phenotypes were highest 1–3 days post onset and
returned to post-recovery levels by 6–8 days post-onset (Figure 3a).
Absolute counts for CD27+CD28+ CD8 T-cells were also lowest
1–3 days post-onset but CD27+CD282 and CD272CD282
CD8 T cell counts were not increased (Figure 3b). The percentage
and number of CD8 T-cells with a CXCR3
highphenotype was
significantly lower 1–3 days after onset than following recovery
and gradually increased.
CD8 T cell activation and differentiation in severe
compared to mild influenza
The peak percentage of CD8 T cells expressing CD38 and
HLADR activation markers was higher in severe influenza (30%,
(4–89%), p=0.019), but varied widely in terms of timing and
magnitude (Figure 4a, Figure S3). In 4 severe patients more than
30% of CD8 T cells were CD38+HLADR+ by day 8 of illness. In
the remainder the percentage CD38+HLADR+ was low or
increased more than 9 days after onset whereas activated CD8
T-cell frequencies were declining by this time in mild illness. The
caveat being that 3 severe patients presented more than 8 days
after onset such that an earlier activation response may have been
missed. Differentiation and extravasation marker expression also
varied markedly (Figure 4 b&c) and was significantly associated
with activation marker expression in severe influenza (Figure 4g).
Figure 1. Detection of influenza virus RNA in respiratory specimens from patients with severe versus mild influenza. Nose and throat
swabs were assessed for the presence of viral RNA as described in the methods. Red dots/lines indicate the first and last days from fever onset when
viral RNA was detected, the first day being when the first sample was collected. Blue dots represent the last day that samples were tested.
doi:10.1371/journal.pone.0031535.g001
Lymphocytes and Influenza Severity
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31535CD27+CD282/partially differentiated (Figure 4b), CDlla
high
(Figure 4e) and CCR5
high (Figure 4f) cells predominated amongst
CD8 T cells from patients with excessive activation. Consequently,
the percentage of CD8 T cells with a CD272CD282/fully
differentiated phenotype was low in these patients (Figure 4c).
Discussion
In this study we demonstrate that acute immune responses
following 2009 H1N1 infection differ between previously healthy
young adults that develop severe versus mild illness. Lymphopenia
was significantly more common in severe illness and CD4 and NK
cells were the major subsets contributing to lymphopenia, with no
detectable B cell involvement. CD8 lymphopenia was detected in
fewer severe patients but was still more common than in patients
with mild illness. The CD8 T cell activation and differentiation
response also differed, being rapid, transient and modest in
patients with mild illness but delayed and/or excessive in patients
with severe illness.
Mechanisms contributing to lymphopenia include reduced
lymphocyte production, increased apoptosis or necrosis, and/or
increased lymphocyte marginalization or trapping. As will be
discussed, all of these mechanisms have been implicated in
lymphopenia during severe influenza infection but the predispos-
ing factors have not been fully elucidated and it is not know if
lymphopenia contributes to severity or is a consequence.
Lymphopenia has been associated with the severity of infection
with influenza A viruses that vary in intrinsic virulence including
pandemic H1N1 [10,32–33], seasonal A/H3N2 [34], and A/
H5N1 [35–37]. Lymphopenia was also observed in nearly one
third of mild influenza cases but was relatively transient, consistent
with reports elsewhere [1,38–40], and probably reflects transient
loss of T cells from the blood as they migrate to draining lymph
nodes [19]. This process is unlikely to adequately account for the
severe and prolonged lymphopenia observed in severely ill
patients. A substantial proportion of severe patients remained
lymphopenic 9–11 days post onset, similar to reports for severe
pandemic H1N1 patients from China [33]. In the current study
lymphocyte subset counts were also performed, which clearly show
that lymphopenia is predominantly attributable to CD4 and NK
cell depletion. Several other studies also find that lymphopenia is
associated with CD4 T cell depletion in severe and/or mild
influenza [33,41–43]. Consequently inverted CD4:CD8 ratios
were more common in severe patients. In 60% of severe patients
CD8 T-cell counts also fell below the normal range whereas the
remainder had normal or high CD8 counts as well as excessive
CD8 T-cell activation. This indicates that the mechanism
underlying lymphopenia may affect both T cell subsets but losses
in the CD8 subset may be offset by activation and proliferation.
Lymphopenia in mice infected with highly pathogenic H5N1 is
associated with increased in situ detection of apoptotic cells in lung
and lymphoid tissue [44] and lymphoid atrophy has been observed
in several severe 2009 H1N1 patients [45]. A large proportion of
lymphocytes undergo apoptosis following antigen driven activation
and expansion [46], and activated CD8 T cell frequencies were
high in severe influenza indicating that activation induced
apoptosis may contribute to lymphopenia. Moreover, others have
demonstrated that activated CD4 T cell frequencies are also
higher in severe 2009 H1N1 infection [47] and that a greatly
increased and massive proportion of CD4 T cells express CD95
(the death receptor), with a lesser increase in the proportion of
CD8 T cells expressing CD95 [41]. The association between
activation, apoptosis and peripheral T cell depletion is best
described for HIV infection where depletion is also greatest
amongst the CD4 subset, a phenomenon attributed to greater
expansion potential of CD8 than CD4 T cells following activation
[46]. There was a weak association between higher values in semi-
quantitative assessment of viral RNA and lower CD4 counts. This
could reflect increased virus replication following CD4 depletion
or vice versa high or prolonged virus replication could cause CD4
depletion via activation and apoptosis, or via release of cytokines
that induce lymphocyte marginalization by adhering to endothe-
lial cells [48–49]. Given the imbalance between CD4 and CD8 T
cells we favor the hypothesis that high or continued viral
replication promotes CD4 depletion. Reduced thymic T cell
output has been implicated in lymphopenia following H5N1
infection in mice, and is a consequence of infection of dendritic
cells that migrate to the thymus and facilitate infection and
destruction of thymic cells [50]. It is plausible that thymic output
could be compromised in severe 2009 H1N1 because virus has
been detected in dendritic cells and thymic epithelial cells from
severe but not mild cases; albeit to a far lesser extent and the
thymus is not damaged [50]. In this regard, viremia was observed
Table 2. Analysis of lymphocytes and subsets.
Mild Severe p
Status at Enrolment * n/N (%)
Lymphopenia 10/39 (26) 6/9 (67) 0.044
CD3 T lymphopenia 12/39 (31) 5/9 (56) 0.247
CD4 T lymphopenia 9/39 (23) 7/9 (78) 0.004
CD8 T lymphopenia 6/39 (15) 5/9 (56) 0.020
NK lymphopenia 1/39 (3) 6/9 (67) ,0.001
CD19 B lymphopenia 1/39 (3) 0/9 (0) 1.000
Status while admitted
Lymphopenia 12/39 (31) 8/10 (80) 0.009
CD3 lymphopenia 15/39 (38) 7/10 (70) 0.090
CD4 lymphopenia 11/39 (28) 9/10 (90) 0.001
CD8 lymphopenia 7/39 (18) 6/10 (60) 0.014
NK lymphopenia 5/39 (13) 10/10 (100) ,0.001
CD19(B) lymphopenia 3/39 (8) 2/10 (20) 0.267
Status at Follow-up **
Lymphopenia 2/19 (10) 1/8 (12) 1.000
CD3 T lymphopenia 2/19 (10) 1/8 (12) 1.000
CD4 T lymphopenia 1/19 (5) 0/8 (0) 1.000
CD8 T lymphopenia 0/19 (0) 0/8 (0) 1.000
NK lymphopenia 1/19 (5) 1/8 (12) 0.513
CD19 B lymphopenia 0/19 (0) 1/8 (12) 0.258
Nadir values Median cells/ml (10–90% range)
CD45+/lymphocytes 1625 (983–2155) 930 (577–1527) ,0.001
CD3 T cells 1019 (699–1683) 535 (385–1272) 0.003
CD4 T cells 543 (346–901) 261 (53–570) ,0.001
CD8 T cells 324 (203–602) 215 (149–830) 0.196
NK cells 245 (143–537) 111 (39–135) ,0.001
CD19 B cells 155 (104–240) 97 (48–443) 0.110
CD4:CD8 ratio 1.32 (0.83–2.06) 0.92 (0.14–1.50) 0.005
*1 severely ill patient was not assessed at enrolment.
**The day post-onset for follow-up assessments was 35 (31–47) for mild
patients and 34 (31–37) for severe patients.
doi:10.1371/journal.pone.0031535.t002
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viremia is associated with severity and lymphopenia [45,51].
Reactive hemophagocytosis is seen in lymph nodes and bone
marrow of some severe 2009 H1N1 patients [45] and this may
contribute to lymphopenia.
Studies of NK cells during human influenza are more limited.
One study found that the percentage of NK cells amongst
peripheral blood mononuclear cells was low in 3 severe pandemic
H1N1 patients with pre-existing conditions compared to 4 mild
patients, but the severe patients were not examined until more
than 18 days post onset. Another found that NK cells were
decreased as a percentage of lymphocytes in children with
moderate and severe influenza [52]. NK cells can be directly
infected by influenza virus and thereafter killed via apoptosis [53],
and this may contribute to NK cell depletion. The present study
demonstrating a dramatic reduction in absolute NK and T cell
counts in the first few days of symptoms followed by a gradual
recovery lends support to the notion that severe illness may be a
consequence of impaired NK and T cell responses. Furthermore,
T cell and NK cell counts returned to normal following recovery
indicating that there is no inherent deficiency.
The loss of both T and NK cells during severe influenza may be
linked to the feedback between these subsets required to control
influenza virus replication. NK cells play a vital role in the early
control of influenza virus replication and their depletion leads to
increased morbidity and mortality in animal models [54–55]. NK
cells bind to and kill infected cells via NK receptor-NKp46
recognition of influenza haemagglutinin [55]. NK cells also
promote T cell recruitment by producing IFN-c, which induces
expression of T cell chemoattractants, MIG and IP-10 [56]. In
turn, the NK cell response to influenza is enhanced by IL-2
produced by preexisting influenza-specific memory T cells [57],
which helps to counteract killing or inhibition of NK cells by
influenza virus [53,58]. Thus, NK cell responses may be
overwhelmed if memory T cells are lacking and high or prolonged
virus replication may subsequently lead to CD4 T cell depletion
via the mechanisms described earlier. In this and other reported
studies it has been difficult to determine if severity is associated
with differences in virus replication because of late presentation of
severe cases [41,45], however there is some evidence of a slower
decline in virus shedding in severe cases [45]. It is also possible that
T cells accumulate in the lungs of severe influenza patients and
contribute to pathology. However, lung tissues from infants with
fatal influenza demonstrate a near absence of CD8 T cells and NK
cells such that severity has been attributed to inadequate rather
than excessive immune responses [59].
Mild influenza illness was associated with transient expression of
activation markers CD38 and HLADR on a small percentage and
Figure 3. Activation, differentiation and extravasation marker expression by CD8 T cells over the course of mild influenza A illness.
The percentages (a) and absolute count (b) of CD8 T cells with the phenotypes CXCR3
high (green lines); CD27+CD28+ (brown lines); CD27+CD282(red
lines); CD272CD282 (yellow lines); CD38+HLA-DR- (light blue lines) and CD38+HLADR+ (dark blue lines) is shown for 39 patients with mild influenza
illness at different time intervals post-fever onset. The number tested during each time interval was 28, 34, 39, 19 and 9. Asterisks indicate where
values differ significantly via paired t-Test from levels at recovery (*), or at recovery and day 1–3 (**), or at recovery and at earlier time intervals (***).
doi:10.1371/journal.pone.0031535.g003
Figure 2. T and NK cell counts in severe versus mild influenza. Panel’s a–c show lymphocyte subset counts by time interval since onset with
each line representing an individual patient. Horizontal solid lines represent the lower limit of the normal range. Panels d–f show nadir values for
lymphocyte subset counts versus pandemic medical early warning score (PMEWS) with Spearman’s correlation coefficients. The 2 patients that died
are indicated ( ) because they were only assessed at one or two time points. Results are shown for 10 patients with severe illness (red tone symbols
and lines) and 39 patients with mild illness (blue tone symbols and lines).
doi:10.1371/journal.pone.0031535.g002
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influenza specific [29] with a minor fraction specific for persistent
viruses [60]. As found elsewhere, activated cells could be detected
within 3 days of mild influenza onset [60] consistent with the time
required for memory cells to respond [61]. CD8 T cell activation
was accompanied by depletion of CD8 T-cells with a resting
(CD27+CD28+) phenotype without accumulation of partially
(CD272CD282) or fully (CD272CD282) differentiated pheno-
types indicating that differentiated effectors migrate to the site of
infection. Cells expressing CXCR3, a chemokine receptor
expressed by activated T cells that facilitates extravasation into
inflamed sites [62], were also depleted. CD8 T cell activation and
differentiation varied markedly within the severe patient group. In
some activation was excessive and resting phenotype cells were
depleted with concomitant accumulation of partially differentiated
cells. In most of the remaining severe patients activation was
delayed, peaking more than 9 days post onset when activation was
resolving in mild illness. A similar phenomenon has been
described for CD4 T cells whereby severe infection is associated
with the production of anergic rather than effector CD4 T cells
[41]. Studies of HIV indicate that partially differentiated CD8 T
cells may have limited antiviral function because they fail to
produce perforin and TNF-a and accumulation is associated with
symptom progression [31,63]. Aberrant or delayed CD8 activation
and differentiation may also affect recruitment to the lungs where
they are required to support NK cells and control virus replication.
This study represents a comprehensive analysis of a relatively
large group of clinically well-characterized 2009 H1N1 patients
but has a number of limitations. The late presentation of severe
patients is such that we can not exclude the possibility that
lymphocyte activation occurred before presentation. For the same
reason viral loads were not informative. We rarely detected viral
RNA in respiratory specimens collected from severe patients after
enrolment, particularly using the quantitative PCR, which was less
sensitive than the CDC influenza A real-time PCR. Although
respiratory samples collected during screening were all positive for
2009 H1N1 in the PCR, they were not assessed in the quantitative
PCR because nose and throat swabs were pooled for screening but
collected separately following enrollment. Commencement of
oseltamivir treatment was also relatively delayed in severe patients
and this may have contributed to severity, although virus clearance
times did not differ significantly. It was not possible to obtain
sufficient blood to determine the frequency of influenza specific
cells by ex-vivo restimulation of purified mononuclear cells so we
could not verify whether HLA-DR+ CD38+ are influenza specific.
Finally, the ability to assess effector cells is limited because they
appear to be very transient within the blood compartment.
Despite the limitations the results demonstrate that severe
influenza is associated with transient T and NK cell deficiency and
with delayed or aberrant CD8 effector cell development.
Importantly, the patients studied had no known pre-existing
illness or obvious inherent NK or T cell deficiency yet succumbed
to a virus that generally causes little or no illness. In contrast to NK
cells, T cell responses depend on past infection history and can
therefore vary widely between healthy individuals. CD8 responses
could be delayed or aberrant during severe influenza because pre-
existing memory T cells are lacking. Longitudinal cohort studies
are required to verify this and the role of memory T cells in clinical
protection against influenza.
Materials and Methods
Patient recruitment and clinical investigations
This study was conducted at the National Hospital of Tropical
Diseases (NHTD), a 160 bed tertiary care centre for adult patients
with infectious disease in Ha Noi that also serves as a referral
centre for general tropical disease in northern Viet Nam. All
patients presenting with influenza-like-illness (ILI) during the first
wave of the 2009 H1N1 pandemic were tested by RT-PCR (as
described below) and admitted if positive, in accordance with
hospital and Ministry of Health policy at the time. ILI was defined
as a history of fever within 7 days prior to presentation plus any
two of cough, myalgia, lethargy, sore throat or runny nose.
Patients admitted with virologically confirmed influenza were
asked to participate in oseltamivir treatment trials (NCT00298233
[standard vs double dose oseltamivir in severe influenza] and
NCT00985582 [oseltamivir treatment of 2009 H1N1]). The
immunological investigations described in this study were
performed as part of these trials. Trial protocols were approved
by the NHTD scientific and ethical committee and by the Oxford
University Tropical Research Ethics Committee. Patients or a
parent or legal guardian provided written informed consent to
participate. In NCT00298233 patients aged over 1 year with
severe virologically confirmed influenza with illness for ,10 days
were enrolled into an oseltamivir dosage trial and randomized to
standard or double dose. Severe illness was defined as one of the
following: new infiltrate on chest X-ray; severe tachypnea
(respiratory rate $30 for age’s $12 years); severe dyspnoea
(unable to speak full sentences or use accessory respiratory
muscles); arterial oxygen saturation #92% on room air by trans-
cutaneous method; requiring mechanical ventilation at presenta-
tion. Patients were excluded from enrollment if they had received
more than 72 hours of oseltamivir (six doses) or received
oseltamivir at higher than standard doses within the last 14 days.
In NCT00985582 patients aged over 1 month with virologically
confirmed 2009 H1N1 influenza were enrolled into a single arm
clinical, virological and pharmacological study to assess the use of
oral oseltamivir. Mild influenza was defined as fever within the
past 7 days plus any two of cough, myalgia, lethargy, sore throat or
runny nose. Only patients aged .15 years with RT-PCR
confirmed 2009 H1N1 and without underlying conditions were
analysed in this study.
Patients were examined daily during hospitalization by a team
of physicians with experience in influenza diagnosis and treatment.
Chest X-ray was performed at enrollment, day 5 and 10.
Virology
Nasal and oropharangeal (throat) swabs were collected at
screening, and on study days 0–10 and 14 using MicroTestM4H
viral collection kits (Remel, Lenexa (KS), USA). If the patient was
mechanically ventilated an endotracheal aspirate was collected. All
respiratory samples were assessed by real-time reverse-transcrip-
tase polymerase chain reaction (RT-PCR), according to WHO/
USCDC protocols (CDC reference no. I-007-05, Accessed
Figure 4. Activation and differentiation marker expression by CD8 T cells from patients with severe versus mild influenza. Panels a–f
show the percentages of cells expressing the markers indicated on the vertical axis by time interval since onset. Each line represents an individual
patient. Panel g shows the relationship between the percentages of CD8 T cells that are CD38+HLADR+ and CD27+CD282 and includes results for all
time points. Results are shown for 10 patients with severe influenza (red tones symbols and lines) and 39 patients with mild influenza (blue tone
symbols and lines).
doi:10.1371/journal.pone.0031535.g004
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pdf). Quantitation of influenza A RNA was performed on positive
samples using a real-time RT-PCR assay, as described previously [64].
The PCR uses primers that amplify a 95 bp section of the M gene:
forward 39-GACAAGACCAATCCTGTCACCTCTG-59, reverse
39AAGCGTCTACGCTGCAGTCC-59, probe bp 190 59TTC-
ACGCTCACCGTGCCCAGTGAGC39. The limit of detection of
this assay is 1000 copies of RNA per milliliter.
Immune Phenotyping
Two ml venous blood samples were collected into ethylenedi-
aminetetraacetic acid (EDTA) vacutainers on study days 0, 2, 5
and 28 for patients NCT00985582 and on days 0, 5, 10, 14 and 28
for patients in NCT00298233. All monoclonal antibodies and
reagents were obtained from BD Biosciences (San Jose (CA),
USA). Absolute counts were performed within 8 hours of blood
collection using a single-platform, lyse no-wash procedure. Briefly,
50 ml of whole blood was incubated with 10 ml of Multitest 6-color
TBNK Reagent in TruCount tubes for 20 minutes. 450 mlo f
FACSlysing solution was added and cell counts determined within
1 hour on a FACSCanto machine (BD Biosciences) using CD45
versus side scatter to gate on lymphocytes and CD3 to gate on T
cells. The activation and differentiation status of T cell subsets was
determined by 6-colour flow cytometry. The activation marker
mix consisted of HLA-DR (FITC) (2 ml), CD69 phycoerythrin (PE)
(2 ml), CD38 PerCP-Cy5.5 (1 ml), CD3PECy7 (2 ml), CD4 APC
(2 ml), CD8 APC-Cy7 (1 ml). The differentiation marker mix
consisted of CD27 FITC (2 ml), CD28 PE (2 ml), CD3PECy7
(2 ml), CD4 APC (2 ml) and CD8 APC-Cy7 (1 ml). Cells were
stained and assessed as above with the exception that forward
scatter versus side scatter was used to define the lymphocyte gate.
All samples were assessed using the same quadrants to define the
percentages of CD8+ and CD4+ CD3 T cells expressing CD27
and CD28 or CD38 and HLA-DR.
Analysis
Illness day was calculated from the first date of ILI symptoms,
which was assigned as day 0. Proportions were compared using
odds ratios and Chi-Square or Fishers exact test when any
expected cell count was less than 5. Continuous variables were
presented as medians and 10–90% ranges and compared using
Mann Whitney tests. In patients with mild illness lymphocyte
counts and percentages at different days from onset were
compared using paired t-Test.
Cut-offs foridentifyinglymphopenia werederived from valuesfor
recovered patients (n=49) assessed during follow-up visits in this
andotherstudies.Normalranges,defined asthegeometricmean +/
22 standard deviations, were as follows: CD45/lymphocytes
1328–3440; CD3 T cells 900–2653; CD4 T cells 451–1209; CD8
T cells 250–1335; CD19 B cells 82–533; and NK cells 147–558.
Lymphocyte counts and percentages were also correlated with
their Pandemic Medical Early Warning Score (PMEWS) score
[65], adapted to include 1 point each if the patients was
hospitalized $14 days or was given supplemental oxygen and
2 points if they were mechanically ventilated. Pearson’s correlation
was used for normally distributed variables and Spearmans for
non-parametric variables, i.e. variables for which the Shapiro
Wilks test was significant.
Analyses were performed with SPSS for Windows, Rel.
14.0.0.245, 2005 (SPSS Inc. Chicago (IL), USA).
Supporting Information
Figure S1 Patients enrolled and excluded from analysis.
(TIF)
Figure S2 Association between PCR cycle threshold (Ct)
value for viral RNA detection and CD4 count. Results are
shown for severe (filled circles) and mild (open triangles) patients
with a Ct value ,40 in CDC influenza A realtime PCR that had
peripheral blood CD4 count performed on the same day. Results
are shown for illness days 3 (red), 4 (blue), 5 (green), and 6 (purple).
Ct values represent the number of cycles required for PCR
product levels to exceed the detection threshold and increase as
the concentration of viral RNA decreases.
(TIF)
Figure S3 Representative FACS plots showing activation
and differentiation marker expression by CD8 T-cells.
Contour plots depict HLADR versus CD38 and CD27 versus
CD28 marker expression by CD3+ CD8+ T-cells from 1 mild
influenza patient with , median values for all markers, and 3
severe influenza patients with different expression profiles.
(TIF)
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